季节性流感疫苗的预防与控制:免疫实践咨询委员会建议——美国2025-26流感季
本报告更新了免疫实践咨询委员会(ACIP)关于美国季节性流感疫苗使用的2024-25建议。建议所有≥6月龄且无禁忌证者每年常规接种流感疫苗。2025-26季更新包括疫苗抗原组成、FluMist(LAIV3)获批自我或照护者给药、Flublok(RIV3)年龄适应证从≥18岁改为≥9岁,以及ACIP新建议:≤18岁儿童、孕妇和所有成人仅接种不含硫柳汞防腐剂的单剂型流感疫苗。
要点
- 所有≥6月龄且无禁忌证者建议每年常规接种季节性流感疫苗。
- 2025-26季预计供应三价灭活流感疫苗(IIV3)、三价重组流感疫苗(RIV3)和三价减毒活流感疫苗(LAIV3)多种剂型。
- ACIP新建议:≤18岁儿童、孕妇和所有成人仅接种不含硫柳汞防腐剂的单剂型流感疫苗。
核心结论
- 所有≥6月龄且无禁忌证者建议每年常规接种季节性流感疫苗。
- 2025-26季ACIP新建议:≤18岁儿童、孕妇和所有成人仅接种不含硫柳汞防腐剂的单剂型流感疫苗。
研究设计与样本
- 本报告为免疫实践咨询委员会(ACIP)关于美国2025-26流感季季节性流感疫苗使用的建议更新,更新自2024-25建议。
主要发现
- 2025-26季预计供应三价灭活流感疫苗(IIV3)、三价重组流感疫苗(RIV3)和三价减毒活流感疫苗(LAIV3)多种剂型。
- 2025-26季更新包括2025-26美国季节性流感疫苗的抗原组成。
- FDA批准FluMist(LAIV3)用于自我给药或照护者给药。
- FDA批准Flublok(RIV3)年龄适应证从≥18岁改为≥9岁。
- ACIP新建议:≤18岁儿童、孕妇和所有成人仅接种不含硫柳汞防腐剂的单剂型季节性流感疫苗。
关键数值与推荐
- 所有≥6月龄且无禁忌证者建议每年常规接种季节性流感疫苗。
- ACIP建议≤18岁儿童、孕妇和所有成人仅接种不含硫柳汞防腐剂的单剂型季节性流感疫苗。
- Flublok(RIV3)年龄适应证为≥9岁。
临床怎么用
- 所有≥6月龄且无禁忌证者每年常规接种季节性流感疫苗。
- ≤18岁儿童、孕妇和所有成人仅接种不含硫柳汞防腐剂的单剂型季节性流感疫苗。
- 2025-26季可使用IIV3、RIV3或LAIV3,具体剂型按年龄与批准适应证选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This report updates the 2024-25 recommendations of the Advisory Committee on Immunization Practices (ACIP) concerning the use of seasonal influenza vaccines in the United States. Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have a contraindication to vaccination. Multiple formulations of the trivalent inactivated influenza vaccines (IIV3s), trivalent recombinant influenza vaccine (RIV3), and trivalent live attenuated influenza vaccine (LAIV3) are expected to be available for the 2025-26 influenza season. Updates for the 2025-26 season include 1) antigenic composition of 2025-26 U.S. seasonal influenza vaccines, 2) Food and Drug Administration (FDA) approval of FluMist (LAIV3) for self-administration or caregiver administration, 3) FDA approval of a change in age indication for Flublok (RIV3) from ≥18 years to ≥9 years, and 4) a new ACIP recommendation that children aged ≤18 years, pregnant women, and all adults receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative. A comprehensive summary of recommendations, including those discussed in this report, as well as previous recommendations concerning topics not addressed in this report and that remain unchanged for the 2025-26 season, is available at Influenza | ACIP Recommendations for Vaccination. Additional background information also is available at Prevention and Control of Seasonal Influenza with Vaccines.
引用
- Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025-26 Influenza Season. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40879559. doi:10.15585/mmwr.mm7432a2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。